Compass Therapeutics (CMPX) Net Income towards Common Stockholders (2023 - 2025)
Historic Net Income towards Common Stockholders for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$15.8 million.
- Compass Therapeutics' Net Income towards Common Stockholders fell 2923.44% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 4154.73%. This contributed to the annual value of -$56.6 million for FY2024, which is 3325.41% down from last year.
- Per Compass Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$15.8 million for Q3 2025, which was down 2923.44% from -$21.1 million recorded in Q2 2025.
- Compass Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$7.8 million during Q1 2023, with a 5-year trough of -$21.1 million in Q2 2025.
- In the last 3 years, Compass Therapeutics' Net Income towards Common Stockholders had a median value of -$13.1 million in 2024 and averaged -$13.5 million.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 1594.25% in 2024, then crashed by 6110.43% in 2025.
- Over the past 3 years, Compass Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$13.4 million in 2023, then decreased by 23.55% to -$16.6 million in 2024, then grew by 4.57% to -$15.8 million in 2025.
- Its Net Income towards Common Stockholders stands at -$15.8 million for Q3 2025, versus -$21.1 million for Q2 2025 and -$16.6 million for Q1 2025.